<DOC>
	<DOCNO>NCT01138137</DOCNO>
	<brief_summary>RATIONAL FOR STUDYING IV NAC AS POTENTIAL CHEMOPROTECTANT : Cisplatin show efficacy treatment subject epithelial ovarian cancer . Systemic toxicity associate cisplatin include nephro , oto , nerve toxicity . It may possible reduce toxicity cisplatin administer conjunction IV NAC . NAC may reduce cisplatin related nephro , oto , nerve toxicity without compromise effectiveness chemotherapy ovarian cancer cell . It possible combination drug may future allow ovarian cancer patient receive full series IP cisplatin-paclitaxel chemotherapy , few side effect improve survival . It hypothesize propose treatment stage III IV epithelial ovarian cancer IP cisplatin IV/IP paclitaxel conjunction IV NAC limit neurotoxicity , nephrotoxicity ototoxicity associate cisplatin administration .</brief_summary>
	<brief_title>N-acetylcysteine Given IV With Cisplatin Paclitaxel Patients With Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : PRIMARY : To determine Maximum Tolerated Dose ( MTD ) ass toxicity IV NAC conjunction IP cisplatin IV/IP paclitaxel subject stage 3 4 epithelial ovarian cancer surgically debulked SECONDARY : - To describe tumor response subject receive treatment previously debulked stage 3 4 epithelial ovarian cancer IP cisplatin , IV/IP paclitaxel , IV NAC . - To describe incidence severity nephrotoxicity ( Creatinine Clearance ( CrCl ) ) subject undergoing treatment stage 3 4 epithelial ovarian cancer IP cisplatin , IV paclitaxel IV NAC disease surgically debulked . - To describe incidence severity hear loss subject undergoing treatment stage 3 4 epithelial ovarian cancer IP cisplatin , IV/IP paclitaxel IV NAC disease surgically debulked . - To describe incidence severity peripheral autonomic neuropathy subject undergoing treatment stage 3 4 epithelial ovarian cancer IP cisplatin , IV/IP Taxol IV NAC disease surgically debulked . OUTLINE : Subjects undergo chemotherapy epithelial ovarian cancer paclitaxel IV , 135 mg/m2 ( Day 1 ) IP cisplatin 100 mg/m2 ( Day2 ) , follow Taxol IP , 60 mg/m2 ( Day 8 ) every 3 week 6 course . Sixty minute prior course IP cisplatin , IV NAC ( start 150 mg/kg ) infuse 30 minute . A dose escalation schema NAC follow . Toxicity therapy grade accord Common Terminology Criteria Adverse Events .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Signed write informed consent accordance institutional guideline Histologically confirm diagnosis stage 3 4 epithelial ovarian primary peritoneal carcinoma Have debulking surgery optimal tumor cytoreduction Standard treatment offer ovarian cancer include systemic intraperitoneal cisplatin systemic taxanebased chemotherapy Age ≥ 18 year ≤ 75 year Laboratory test within 14 day registration : White blood cell count ≥ 2.5 x 103/mm3 Absolute granulocyte count ≥ 1.2 x 103/mm3 Platelets ≥ 100 x 103/mm3 Creatinine &lt; 1.8 Bilirubin &lt; 2.0 Serum glutamate oxaloacetate transaminase ( SGOT ) /Serum glutamate pyruvate transaminase ( SGPT ) &lt; 2.5 x institutional upper limit normal Performance status must Eastern Cooperative Oncology Group ( ECOG ) &lt; 2 ( Karnofsky ≥ 50 ) Life expectancy ≥ 60 day date registration Pregnant , positive beta human chorionic gonadotropin ( hCG ) , lactate History clinically significant reactive airway disease Active significant cardiac disease evidence New York Heart Association Classification chronic heart failure ( CHF ) , Class III IV Uncontrolled ( last 30 day ) clinically significant confound medical condition Allergies contraindication IP cisplatin , IV Taxol , IV NAC .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>epithelial ovarian cancer</keyword>
	<keyword>peritoneal cancer</keyword>
</DOC>